AstraZeneca PLC - Form 6-K Filing Summary

This report details the positive interim analysis of the I CAN Phase III trial for Ultomiris (ravulizumab) in treating immunoglobulin A nephropathy (IgAN). The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful reduction in proteinuria at week 34. Ultomiris showed rapid reduction in proteinuria as early as week 10, indicating its potential as a disease-modifying treatment for IgAN. The study involved adults with IgAN at risk of disease progression, and the observed safety profile was consistent with Ultomiris's known profile. AstraZeneca plans to seek accelerated approval and present these findings at a medical meeting. The report also provides background on IgAN, the I CAN trial design, and details about Ultomiris and its other approved indications.